Publications

 

Dr. Oldham's Publications:

 

  Oldham R.K. Why We Need to Rethink the Regs. Genome Technology Op/Ed August 2001

  Oldham R.K. Our Bodies, Our Cells? Wall Street Journal Op/Ed 6/4/01

  Oldham R. K. Stem Cells: Private Sector Can Do It Better Wall Street Journal Op/Ed 8/28/01

  Oldham R.K. Informed Opinions: Editorial Introduction Cancer Biotherapy and Radiopharmaceuticals 17(3) 247 2002

  Oldham R.K. and Dillman R.O. Editorial: Gold Standard or Wrong Standard? Cancer Biotherapy and Radiopharmaceuticals, 19(3) 271-272, 2004

  Oldham R.K. Unlucky Jim Wall Street Journal Op/Ed 2/16/05

  Robey R.W. Shukla S. Finley E.M. Oldham R.K. Barnett D. Ambedkar S.V. Fojo T. and Bates S.E. Inhibition of P-glycoprotein (ABCC)-mediated transport by the orally administered inhibitor, CBT-1 Biochem Pharm 75:1302-1312, 2008

  Oldham R.K. and Dillman R.O. Monoclonal Antibodies in Cancer Therapy: Twenty-Five Years of Progress. JCO 26(11):1774-1777.

  Cancer Biotherapy: General Principles- Robert K. Oldham, Principles of Cancer Biotherapy, 5th Edition, Springer 2009

  Developmental Therapeutics and Genomics In Cancer Therapy- Robert K. Oldham, Principles of Cancer Biotherapy, 5th Edition, Springer 2009

  Current Concepts in Immunology- Robert K. Oldham, Principles of Cancer Biotherapy, 5th Edition, Springer 2009

  Therapeutic Approaches to Cancer-Associated Immune Suppression Robert K. Oldham, Principles of Cancer Biotherapy, 5th Edition, Springer 2009

  Cytokines- Walter M. Lewko and Robert K. Oldham, Principles of Cancer Biotherapy, 5th Edition, Springer 2009

  Stem Cell/Bone Marrow Transplantation as Biotherapy- Robert K. Oldham, Principles of Cancer Biotherapy, 5th Edition, Springer 2009

  Growth and Differentiation Factors as Cancer Therapeutics- Kapil Mehta, Robert K. Oldham, and Bulent Ozpolat, Principles of Cancer Biotherapy, 5 th Edition, Springer 2009

  Cancer Biotherapy: 2009 Disease-related Activity- Robert K. Oldham and Robert O. Dillman, Principles of Cancer Biotherapy, 5th Edition, Springer 2009

  Monoclonal Antibody Therapy of Solid Malignancies pp 217-267 Robert O. Dillman and Robert K. Oldham Immunoglobulin Therapy Eds: A.H. Lazarus and J.W. Semple AABB Press 2010

  Oldham, R.K., Reid, W.K., and Barnett, D. Phase I Study of CBT-1 and Taxol in Patients with Taxol Resistant Cancers. Cancer Biotherapy & Radiopharmaceuticals 15(2):153-160, 2000.

  Oldham, R.K., Reid, W.K., and Barnett, D. Phase I Study of CBT-1 and Taxol in Patients with Taxol Resistant Cancers. Cancer Biotherapy & Radiopharmaceuticals 15(2):153-160, 2000.

  Lewko, Walter M., Hall, Peggy B., and Oldham, R.K. Growth of Tumor-Derived Activated T Cells for the Treatment of Advanced Cancer. Cancer Biotherapy & Radiopharmaceuticals. 15(4):357-366, 2000.

  A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1 in Combination with Paclitaxel in Solid Tumors- Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Calug Z, Frye R, Steinberg S, Fojo T and Bates SF The Oncologist 17(4):512, 2012

  Inhibition of P-glycoprotein(ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1 Robey RW, Skukla S, Finley EM, Oldham RK et al Biochem Pharmacol 75(6):1302

  Oldham R.K. FDA Trials Cost Lives Wall Street Journal Op/Ed 3/3/02